Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01804777 · ClinicalTrials.gov registry record · Early Phase 1
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
A Early Phase 1 study, sponsored by University of New Mexico.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT01804777 is a Early Phase 1 study that was terminated before completion, run by University of New Mexico. The registered enrollment target is 9 participants.
The verdict
NCT01804777, a Early Phase 1 study, was terminated before completion, sponsored by University of New Mexico.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine with the administration of amiloride, observe an enhanced natriuresis, reduction in blood pressure and weight compared to the administration of hydrochlorothiazide in Type 2 Diabetics.
Interventions
- DRUG Amiloride
- DRUG HCTZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01804777
The ClinicalTrials.gov registry entry for NCT01804777 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Amiloride is the first listed.
NCT01804777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01804777 about?
NCT01804777 is a clinical study titled "Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes". The purpose of this study is to determine with the administration of amiloride, observe an enhanced natriuresis, reduction in blood pressure and weight compared to the administration of hydrochlorothiazide in Type 2 Diabetics.
What is the current status of trial NCT01804777?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2013-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01804777?
The interventions under investigation include: Amiloride (DRUG), HCTZ (DRUG).
Who is sponsoring clinical trial NCT01804777?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.